In recent years, various interventional therapies, e.g., edge-to-edge therapies, percutaneous annuloplasty, or orthotopic valve implantation, have emerged to treat symptomatic, inoperable patients wit...

Patients with small annuli are at risk for worse hemodynamic performance after transcatheter aortic valve replacement (TAVR). It is debatable whether a small annulus confers worse outcomes. This study...

Management of aortic stenosis (AS) typically involves surveillance until severe, symptomatic AS develops, at which point aortic valve replacement (AVR) is recommended. However, recent trials suggest t...

Patients with severe tricuspid regurgitation (TR) are at risk for significant morbidity and mortality. Data on long-term clinical outcomes and health care resource utilization for this population are ...

Data regarding change in neurocognitive function after transcatheter aortic valve replacement (TAVR) are conflicting. We sought to investigate the change in cognition up to 6 months post-TAVR in patie...

In the randomized Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT; NCT01626079) trial, mitral transcathe...

Mounting evidence suggests surgical left atrial appendage (LAA) exclusion reduces stroke risk in patients with atrial fibrillation. Prior older research suggests that LAA exclusion is often incomplete...

Opening Thoughts Dear Colleagues, We’re less than a month away from New York Valves™ 2025, and this year’s program is more expansive, innovative, and impactful than ever! The agenda brings together th...

Mitral annular calcification (MAC) is a common finding in the elderly that is associated with worse outcomes. It is postulated that MAC is a different form of atherosclerosis. Epicardial fat tissue (E...

Transcatheter aortic valve implantation (TAVI) is beneficial in low-flow, low-gradient aortic stenosis (LGAS) (mean pressure gradient [MPG] ​<40 mmHg). The benefit and outcomes of TAVI in very low-gra...

Mitral transcatheter edge-to-edge repair (M-TEER) is usually performed in the setting of a hospitalization. Some recent data suggest the safety of a same-day discharge (SDD) approach after M-TEER, but...

A 72-year-old male with a history of hypertension, dyslipidemia, coronary disease with elevated coronary calcium score, and paroxysmal atrial fibrillation (CHA2DS2-VASc score of 3 and HAS-BLED score o...

The prevalence of cardiac amyloidosis (CA) has been increasing regardless of gender, race, or geographic variation.1 Atrial fibrillation (AF) can be seen in up to 70% of patients with CA. Additionally...

There is a high prevalence of significant tricuspid regurgitation (TR) in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER). Significant TR is associated with poor prognosis and af...

The Myval series are novel balloon-expandable transcatheter heart valves (THVs) that feature intermediate (21.5, 24.5, and 27.5 mm) and extra-large (30.5 and 32 mm) sizes in addition to the convention...